Shengqing Gu

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

26h-index7.8kcitations234works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(103), Immune Cell Function and Interaction(43), Estrogen and related hormone effects(34), Immune cells in cancer(29), Immunotherapy and Immune Responses(28)

Publications234 total

Supplementary Table 4 from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
2025Open Access
Supplementary Table 1 from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
2025Open Access
Supplementary Table 3 from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
2025Open Access
Supplementary Figures from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
2025Open Access
Supplementary Table 2 from A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
2025Open Access
Abstract B022: Genetic evolution of immune escape across cancers
Cancer Research·2025
Supplementary Data files from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression
2025Open Access
Supplementary Tables from Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II Expression
2025Open Access
LRP-1 regulates T cell proliferation and activation through global lipid network and loss of LRP-1 eliminates GVHD In Vivo
Blood·2025
Abstract PR014: ARID4B induces immune escape in high-grade serous ovarian cancer by upregulating B3GNT5-mediated glycosphingolipid synthesis
Cancer Research·2025
Figure S6 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Data from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S7 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S5 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S8 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S4 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S2 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S1 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Figure S3 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
2025Open Access
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
Cancer Research·2025· 1 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

X. Shirley Liu(26), Myles Brown(23), Jingxin Fu(18), Zexian Zeng(17), Yi Zhang(16), Wubing Zhang(15), Peng Jiang(13), Xiaoqing Wang(13), Henry W. Long(13), Avinash Sahu(11), Nicole Traugh(10), Paloma Cejas(10), Ziyi Li(9), Clifford A. Meyer(9), Collin Tokheim(9), Benjamin G. Neel(9), Yingtian Xie(8), Klothilda Lim(8), Gordon J. Freeman(7), Kai W. Wucherpfennig(7)